News and Trends 26 Aug 2022 Cholesterol targeting antibodies produced by Bio-Rad Laboratories Antibodies that target a protein playing a key role in the regulation of cholesterol levels have been introduced by Bio-Rad Laboratories. The range of type 1 antibodies inhibit the binding of evolocumab (Repatha) to its target – human proprotein convertase subtilisin/kevin type 9 (PCSK9). Recombinant antibodies These sequence-defined, recombinant antibodies are suitable for developing highly […] August 26, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Aug 2022 Ordaōs raises $5M to accelerate drug design and discovery U.S. biotech company Ordaōs has raised $5 million in seed financing to aid in new product development and expand partner acquisition efforts. The oversubscribed round was led by Middleland Capital’s VTC Ventures with additional investments from Route 66 Ventures, Banyan Pacific Capital, IAG Capital Partners, and Citta Capital. Ordaōs is a drug design company that […] August 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved A treatment for chronic graft versus host disease in children aged one year and older has been approved by the U.S. Food and Drug Administration (FDA). Graft versus host disease is a common complication after receiving a donor stem-cell or bone marrow transplantation. Sometimes, the graft doesn’t recognize the host as being friendly and sees the […] August 25, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 3T Biosciences launches with $40M financing 3T Biosciences wants to change the future of treatment for solid tumors and other immune-mediated diseases. And it exited from stealth today backed by $40 million in series A financing led by Westlake Village BioPartners with participation from Lightspeed Venture Partners. Proceeds from the financing will be used to help accelerate 3T Biosciences from a […] August 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Hera Biotech bags $1.9M for endometriosis diagnostic test San Antonio-based medical device start-up Hera Biotech has closed an oversubscribed $1.9 million seed financing round to support its commercialization strategy for its non-surgical diagnostic test for endometriosis, MetriDx. The funds will be used to complete an in-patient human clinical study, expand Hera’s IP portfolio, and support a regulatory pathway with the U.S. FDA. Investors […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 BioAge partners with Age Labs to study healthy life length BioAge Labs, Inc., a biotech company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, has partnered with Age Labs AS, a diagnostic company that develops tests for the early detection of age-related diseases. Under the terms of the agreement, BioAge will perform multi-omics analyses on samples and health records […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Oncolyze seeking investment for AML clinical trials After successfully completing in vitro and in vivo experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer cells and increases survival rates, Oncolyze now has its sights set on advancing OM-301 into clinical trials. Oncolyze has launched a Regulation A+ funding campaign to spread awareness of OM-301 among cancer patients, […] August 24, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Amgen announces top-line results from biosimilar phase 3 study Amgen has announced positive top-line results from its DAHLIA study. This was a randomized, double-blind, active-controlled, two-period crossover phase 3 study evaluating the efficacy and safety of ABP 959, a biosimilar candidate to SOLIRIS (eculizumab), compared with SOLIRIS in adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Amgen said the study met its primary endpoints, demonstrating […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Freedom Biosciences exits stealth with $10.5M financing to develop mental health treatments Freedom Biosciences, a U.S. clinical-stage biotech platform developing ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing. MBX Capital led the round and was joined by PsyMed Ventures, Village Global and The Yale Startup, among others. The new financing will help the company advance its current lead ketamine program as […] August 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Novel nanotechnology ‘supercharges’ immune system molecules to fight cancer Researchers from Cytimmune Sciences, a clinical-stage biotech company, have presented new data on the company’s novel cancer nanomedicines. The presentation took place at the Cytokine Drug Development Conference held in Boston, Massachusetts, late last month. David Oarr, Cytimmune’s president, participated in the event’s opening panel to discuss the current clinical status and future anticipated progress […] August 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Parkinson’s Foundation and Parkinson’s UK partner to drive drug development The Parkinson’s Foundation and Parkinson’s UK, which funds research and provides support for people with Parkinson’s disease (PD), have announced a new international strategic partnership to boost investment in research on new treatments for PD, which affects 10 million people worldwide. Over the next three years, the Parkinson’s Foundation will invest a minimum of $3 […] August 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2022 Gate Neurosciences emerges from stealth to tackle CNS diseases Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate Neurosciences, a U.S. biotech company, was founded in 2019 by a team of neuroscience industry veterans to address the need for more effective treatments for CNS disorders, and to overcome long-standing challenges […] August 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email